Japan approves ZymeTx' ZstatFlu test:
This article was originally published in Clinica
Executive Summary
ZymeTx has received the go-ahead to market its rapid, point-of-care influenza test, ZstatFlu, in Japan. Clinical trials have shown that the 20-minute, throat-swab-based test can detect both influenza types A and B with a specificity of 99%, says the Oklahoma City, Oklahoma company. The test has also detected variant strains, such as the Hong Kong flu. ZymeTx' CEO Norman Proulx, says that Japan represents the largest market for the test outside the US, where it has been available since 1998. The product will be distributed by Japanese firm, Nichirei.